NY-IFF
2.6.2022 22:17:09 CEST | Business Wire | Press release
IFF (NYSE:IFF) has released its 2021 environmental, social and governance plus sustainable solutions (or ESG+) performance report. Published today, “Transforming Our World ,” details the Company’s commitment to do more good for people and the planet, aligned with IFF’s purpose—Applying science and creativity for a better world. Centered around the recently launched Do More Good Plan , the report updates progress on legacy IFF targets, looks ahead to even more ambitious 2030 objectives, and aims to address the world’s most pressing sustainable development challenges from IFF’s perspective.
A live webcast to discuss the Company’s Do More Good Plan and goals, 2021 ESG+ results, and 2022 outlook will be held on June 9, 2022 at 8:00 a.m. ET.
“At IFF, we’re taking a holistic approach to creating a better world by leveraging our business, performance and partners,” said Frank Clyburn, IFF CEO. “Since the launch of our first sustainability program in 2010, we’ve made tremendous progress. To continue driving results, we’re challenging our teams to be accountable, to collaborate across divisions, and to execute on our ESG+ strategy.”
“At today’s IFF, we’re taking another bold step, embedding a more comprehensive ESG structure in every part of our business, including the solutions we produce to help our customers reach their own ESG goals,” Mr. Clyburn continued. “Following the merger with DuPont’s Nutrition and Biosciences division, this report showcases our first year of results since launching our Do More Good Plan. We’re proud of the many ways we’re becoming a stronger, more resilient company, as we apply science and creativity for a better world.”
The 2021 ESG+ Report aligns with the Do More Good Plan’s four pillars: Sustainable Solutions, Climate and Planetary Health, Equity and Wellbeing, and Transparency & Accountability.
Examples of 2021 performance highlights and achievements include:
- Recognized for ESG leadership: named to the Dow Jones Sustainability Indices for the second consecutive year, received the EcoVadis platinum sustainability rating, and included in the Bloomberg Gender Equality Index
- Enabled and accelerated the wider adoption of sustainable solutions in the marketplace across divisions, and promoted circular economy growth through IFF products verified as Upcycled Certified™
- Continued commitment to climate action—being one of only 14 companies out of nearly 12,000 assessed—named by CDP as a triple A list company for corporate transparency on climate change, water stewardship and deforestation
- Strengthened commitment to diversity, equity and inclusion, honored by the Human Rights Campaign as a Best Place to Work for LGBTQ Equality for the third consecutive year, and named among the Best Places to Work for Disability Inclusion by Disability:IN for the second consecutive year
To read IFF’s 2021 ESG+ Report, click here or visit: https://www.iff.com/responsibilities/strategy-reporting/report-library .
Webcast
A live webcast to discuss the Company’s Do More Good Plan and goals, 2021 ESG+ metrics and performance results, and 2022 outlook will be held on June 9, 2022 at 8:00 a.m. ET. Mr. Clyburn will be joined by Michael DeVeau, Chief Investor Relations & Communications Officer; Dr. Greg Yep, Chief Research & Development, Global Integrated Solutions and Sustainability Officer; Pete Sommers, Interim Chief Human Resources and Diversity, Equity & Inclusion Officer; and Kip Cleverley, Vice President, Global Sustainability & EHS. The webcast and accompanying slide presentation may be accessed on the Company’s Investor Relations website at ir.iff.com .
Investors and analysts are invited to participate by phone by calling 866-342-8591 from the United States and 203-518-9713 from other locations. The access code for the conference call is IFF0609. A live listen-only webcast will also be available at ir.iff.com . For those unable to listen to the live webcast, a recorded version will be made available on the Company’s website approximately one hour after the event.
Welcome to IFF
At IFF (NYSE: IFF)—an industry leader in food, beverage, scent, health and biosciences—science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com , Twitter , Facebook , Instagram , and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220602005744/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom